Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

Shiraz E-Medical Journal

homeHome
play_arrowCurrent IssuelistAll Issuesformat_indent_increaseIn Presscheck_circleAccepted ManuscriptssearchSearch
settingsInstructions
infoJournal InformationgroupsBoards and CommitteesshareIndexing and Listing Sourcesshow_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormcampaignAnnouncementemailSupportphoneContact Us
format_list_bulletedAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)

1. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

- Kumar V. , et al.

2. Imatinib efficacy, safety and resistance in iranian patients with chronic myeloid leukemia: A review of literature

- Amouei A. , et al.

3. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

- Dai J. , et al.

4. Imatinib induced melasma-like pigmentation: Report of five cases and review of literature

- Ghunawat S. , et al.

5. Non-hematological adverse events of imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP)

- Payandeh M. , et al.

6. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor

- Hamza I. , et al.